[HTML][HTML] Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
D Zeng, J Wu, H Luo, Y Li, J Xiao, J Peng… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Journal for immunotherapy of cancer, 2021•ncbi.nlm.nih.gov
Background Durable efficacy of immune checkpoint blockade (ICB) occurred in a small
number of patients with metastatic gastric cancer (mGC) and the determinant biomarker of
response to ICB remains unclear. Methods We developed an open-source TMEscore R
package, to quantify the tumor microenvironment (TME) to aid in addressing this dilemma.
Two advanced gastric cancer cohorts (RNAseq, N= 45 and NanoString, N= 48) and other
advanced cancer (N= 534) treated with ICB were leveraged to investigate the predictive …
number of patients with metastatic gastric cancer (mGC) and the determinant biomarker of
response to ICB remains unclear. Methods We developed an open-source TMEscore R
package, to quantify the tumor microenvironment (TME) to aid in addressing this dilemma.
Two advanced gastric cancer cohorts (RNAseq, N= 45 and NanoString, N= 48) and other
advanced cancer (N= 534) treated with ICB were leveraged to investigate the predictive …
Abstract
Background
Durable efficacy of immune checkpoint blockade (ICB) occurred in a small number of patients with metastatic gastric cancer (mGC) and the determinant biomarker of response to ICB remains unclear.
Methods
We developed an open-source TMEscore R package, to quantify the tumor microenvironment (TME) to aid in addressing this dilemma. Two advanced gastric cancer cohorts (RNAseq, N= 45 and NanoString, N= 48) and other advanced cancer (N= 534) treated with ICB were leveraged to investigate the predictive value of TMEscore. Simultaneously, multi-omics data from The Cancer Genome Atlas of Stomach Adenocarcinoma (TCGA-STAD) and Asian Cancer Research Group (ACRG) were interrogated for underlying mechanisms.
Results
The predictive capacity of TMEscore was corroborated in patient with mGC cohorts treated with pembrolizumab in a prospective phase 2 clinical trial (NCT02589496
ncbi.nlm.nih.gov